Daily Cosmetic Research Analysis
Three impactful studies span surgical infection prevention, dermatologic therapeutics, and aesthetic device–topical synergy. A randomized THA study shows benzoyl peroxide adds no benefit to standard chlorhexidine in reducing Cutibacterium acnes colonization. A meta-analysis confirms mirikizumab’s robust efficacy for plaque psoriasis, while a registered, split-face RCT shows that adding a blueberry extract/Pro‑xylane cream to micro-focused ultrasound enhances anti-aging outcomes.
Summary
Three impactful studies span surgical infection prevention, dermatologic therapeutics, and aesthetic device–topical synergy. A randomized THA study shows benzoyl peroxide adds no benefit to standard chlorhexidine in reducing Cutibacterium acnes colonization. A meta-analysis confirms mirikizumab’s robust efficacy for plaque psoriasis, while a registered, split-face RCT shows that adding a blueberry extract/Pro‑xylane cream to micro-focused ultrasound enhances anti-aging outcomes.
Research Themes
- Preoperative skin microbiome management and infection prevention
- Evidence synthesis for IL-23 pathway biologic therapy in psoriasis
- Synergistic strategies combining energy-based devices with cosmeceuticals
Selected Articles
1. The Frank Stinchfield Award: Preoperative Surgical Skin Cleansing Protocols Are Not Effective at Decreasing the Burden of Cutibacterium acnes Before Total Hip Arthroplasty.
In a randomized comparison of standard chlorhexidine prep versus added 5% benzoyl peroxide applications before THA, there was no reduction in dermal colonization overall or for Cutibacterium acnes specifically. Approximately 11% of biopsies were culture-positive, with similar positivity by group and by anterior versus lateral sampling sites.
Impact: This randomized study challenges the assumption that adding benzoyl peroxide reduces C. acnes burden before arthroplasty, informing preoperative protocols for infection prevention.
Clinical Implications: Routine addition of benzoyl peroxide to standard chlorhexidine skin prep before THA is unlikely to reduce C. acnes colonization; alternative or adjunctive strategies should be considered for high-risk patients.
Key Findings
- Randomized allocation to standard 4% chlorhexidine prep vs. standard plus multiple 5% benzoyl peroxide applications.
- Overall 11% of skin biopsies yielded positive cultures; no difference between groups (STD 38% vs. BPO 41% positive patients; P=0.61).
- C. acnes positivity was similar between groups (STD 17% vs. BPO 20%; P=0.51) and more common than Staphylococcus or Bacillus species.
- No differences in positivity between anterior vs. lateral sampling locations.
Methodological Strengths
- Randomized two-arm design with intraoperative standardized sampling and six punch biopsies per patient.
- Extended culture incubation (14 days) to maximize recovery of slow-growing organisms like C. acnes.
Limitations
- Surrogate outcome (skin colonization) rather than clinical periprosthetic infection rates.
- Sample size and adherence to at-home benzoyl peroxide applications are not detailed in the abstract.
Future Directions: Evaluate alternative preps (e.g., povidone-iodine, alcohol combinations), deeper dermal/sebaceous targeting, and link colonization reduction to infection outcomes in adequately powered RCTs.
BACKGROUND: Cutibacterium acnes (C acnes) is of growing concern in periprosthetic joint infections following total hip arthroplasty (THA). The dermal colonization rate of C acnes with various preoperative cleaning protocols in THA has yet to be elucidated. The purpose of the study was to investigate the effect of different preoperative skin cleansing protocols on the colonization rate of the hip in patients undergoing elective THA. METHODS: Patients were recruited and randomized into either: 1) standard (STD) surgical preparation (4% chlorhexidine gluconate); or 2) STD + benzoyl peroxide (BPO) gel (four applications of 5% BPO gel). On the morning of the biopsy collection, a final application of 5% BPO gel was applied. Intraoperatively, all patients had their skin prepped with STD preparation. There were six 3-mm punch skin biopsies performed per patient for both an anterior-based hypothetical incision and a more lateral/posterior incision. Samples were cultured and held for 14 days. RESULTS: Of the biopsies, 11% had a positive culture. There were 38% of the patients in the STD group and 41% of the patients in the BPO group who had a positive culture (P = 0.61). There were 17% of the patients in the STD group and 20% of the patients in the BPO group who had a positive culture for C acnes (P = 0.51). C acnes was more commonly cultured in both the STD and BPO groups as compared to Staphylococcus species and Bacillus species. There were no differences between positive culture biopsies between anterior or lateral sampling locations (P = 0.62 STD group and P = 0.71 BPO group). CONCLUSIONS: There was a high rate of patients that demonstrated C acnes colonization prior to THA. There was no difference in positive culture rate with anterior or lateral sample locations. Preoperative surgical preparation was not effective at decreasing the burden of C acnes from the surgical site prior to THA, and different skin preparations should be considered.
2. Does Mirikizumab benefit patients with plaque psoriasis? a systematic review and meta-analysis.
Across three RCTs (n=1648), mirikizumab significantly improved PASI 75/90/100 at week 16 versus placebo and enhanced DLQI and sPGA, without observed differences in adverse events at short-term follow-up. These data support efficacy for plaque psoriasis, while long-term safety remains to be clarified.
Impact: This meta-analysis consolidates high-level evidence that mirikizumab yields robust clinical and quality-of-life benefits in plaque psoriasis, informing therapeutic decisions.
Clinical Implications: Mirikizumab is a compelling option for moderate-to-severe plaque psoriasis with strong week-16 efficacy; clinicians should continue to monitor for long-term safety and durability.
Key Findings
- Three RCTs (n=1648) comparing mirikizumab to placebo were synthesized.
- At week 16, PASI 75/90/100 responses were markedly higher with mirikizumab (RR 10.47, 11.5, 25.94; all P<0.00001).
- DLQI, sPGA, and body surface area improved significantly versus placebo (P<0.00001).
- Adverse events did not differ between groups at short-term assessment (p=0.63).
Methodological Strengths
- Inclusion of only randomized controlled trials across multiple databases with consistent outcome measures (PASI, DLQI, sPGA).
- Large combined sample (n=1648) enabling precise estimates of effect sizes.
Limitations
- Only three trials with 16-week primary endpoints; long-term safety and durability not established.
- Potential heterogeneity in trial designs and populations not detailed in the abstract.
Future Directions: Conduct head-to-head trials versus other IL-23/IL-17 inhibitors and long-term safety/efficacy extensions with standardized safety monitoring.
BACKGROUND: Plaque psoriasis is a chronic skin condition characterized by skin scales. It causes a cosmetic problem for patients. Mirikizumab has shown promising results in managing psoriasis. Nevertheless, there remains a dispute over its safety. This systematic review and meta-analysis aimed to assess the effectiveness of mirikizumab in individuals with plaque psoriasis. METHODS: We searched four databases: PubMed, Scopus, Cochrane CENTRAL, and Web of Science. We included trials comparing mirikizumab with placebo in psoriatic patients. Two independent authors extracted data in an Excel sheet. We used RevMan software (version 5.2) to perform meta-analysis. RESULTS: A meta-analysis of three RCTs with a total of 1648 patients was performed. Mirikizumab showed significantly higher rates of PASI 75, PASI 90, and PASI 100 responses at week 16 compared to placebo, with risk ratios (RR) of 10.47, 11.5, and 25.94, respectively (all P < 0.00001). According to adverse events, we found no difference between mirikizumab and placebo. Furthermore, mirikizumab showed significant results compared to placebo in terms of DLQI, sPGA, and body surface area, with P < 0.00001. Unfortunately, there was no difference between the two groups regarding adverse events, with p = 0.63. CONCLUSION: Mirikizumab showed good responses in managing plaque psoriasis. However, additional clinical trials are required to verify its safety and evaluate its long-term efficacy.
3. A Randomized, Investigator-Blinded, Split-Face, Controlled Trial Evaluating the Efficacy and Satisfaction of a Topical Product Containing Blueberry Extract and Pro-Xylane Combined With Micro-Focused Ultrasound for Anti-aging.
In a registered, randomized, investigator-blinded split-face trial (n=50), post‑MFUS application of a blueberry extract/Pro‑xylane cream improved GAIS at Day 90 and enhanced elasticity and fine lines at defined facial sites, with higher patient and dermatologist satisfaction versus standard moisturizer.
Impact: Provides controlled, randomized evidence that targeted cosmeceuticals can augment outcomes of energy-based anti-aging treatments.
Clinical Implications: Post-procedure regimens may benefit from cosmeceuticals with biologically active components (e.g., Pro‑xylane) to enhance elasticity and fine-line outcomes following MFUS.
Key Findings
- Randomized, investigator-blinded, split-face design with 180-day follow-up (NCT05748470).
- GAIS significantly favored the intervention side at Day 90 (p<0.001).
- Improved skin elasticity (cheeks and mouth corners on multiple visits) and fine lines at mouth corners at Day 180 on the intervention side.
- Higher patient and dermatologist satisfaction for the intervention side.
Methodological Strengths
- Randomized split-face design controlling for inter-individual variability with investigator blinding.
- Prospective registration and multidomain outcomes (GAIS, elasticity, lines, dermal thickness, TEWL).
Limitations
- Small, predominantly female cohort (98% female) limits generalizability.
- Split-face design may not blind participants to tactile/cosmetic differences between products.
Future Directions: Larger, multi-ethnic RCTs comparing different active cosmeceuticals and dosing schedules, with longer follow-up and objective biomechanical/biometric endpoints.
BACKGROUND: Micro-focused ultrasound (MFUS) has been effective in treating skin aging, which manifests as skin thinning, reduced elasticity, wrinkling, etc. AIMS: This study aims to evaluate the efficacy and satisfaction of combining a product containing blueberry extract and Pro-xylane (A.G.E. cream) with MFUS in antiaging effects in the Chinese population. METHODS: In this randomized, investigator-blinded, controlled trial, patients aged 18-65 with skin roughness, sagging, laxity, or fine lines/wrinkles were enrolled. After MFUS, one side of patients' faces was randomly assigned to apply the A.G.E. cream and the other side with the standard moisturizer. Patients were followed up for 180 days. The primary endpoint was the Global Aesthetic Improvement Scale (GAIS). Secondary endpoints included percentage changes from baseline in fine lines, skin elasticity, dermal thickness, and transepidermal water loss. Patient and dermatologist satisfaction was evaluated using a questionnaire. RESULTS: A total of 50 patients were included in the study, with 49 (98%) being female. The mean ± SD age was 33.7 ± 6.4 years. For the primary endpoint, the intervention side demonstrated significant improvement in GAIS compared to the control side on Day 90 (p < 0.001). For secondary endpoints, the A.G.E. cream use after MFUS significantly improved skin elasticity at the cheeks and mouth corners on multiple follow-up days and improved fine lines at the mouth corners on Day 180. Patients and dermatologists reported higher satisfaction levels with the aesthetic outcomes of the intervention side. CONCLUSIONS: The application of the A.G.E. cream following MFUS treatment improved skin elasticity, dermal thickness, fine lines, and patient/dermatologist satisfaction. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05748470.